Passage Bio (PASG) Expected to Post Earnings on Monday

Passage Bio (NASDAQ:PASG) will likely be releasing its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($2.27) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($2.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.76) by $0.40. On average, analysts expect Passage Bio to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Passage Bio Stock Down 0.4%

Shares of PASG stock opened at $4.47 on Friday. Passage Bio has a twelve month low of $3.29 and a twelve month high of $20.00. The company has a market cap of $14.35 million, a P/E ratio of -0.38 and a beta of 1.42. The business has a fifty day simple moving average of $5.14 and a 200 day simple moving average of $7.39.

Insider Transactions at Passage Bio

In other news, major shareholder Lynx1 Capital Management Lp bought 50,055 shares of the stock in a transaction on Thursday, June 25th. The stock was acquired at an average price of $4.12 per share, with a total value of $206,226.60. Following the acquisition, the insider directly owned 673,759 shares in the company, valued at approximately $2,775,887.08. This trade represents a 8.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.90% of the stock is currently owned by insiders.

Institutional Trading of Passage Bio

Several hedge funds and other institutional investors have recently made changes to their positions in PASG. Quadrature Capital Ltd acquired a new position in shares of Passage Bio in the fourth quarter valued at approximately $148,000. Squarepoint Ops LLC acquired a new stake in Passage Bio during the 3rd quarter worth approximately $188,000. Geode Capital Management LLC boosted its position in Passage Bio by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock worth $371,000 after buying an additional 4,114 shares during the period. Yiheng Capital Management L.P. bought a new stake in Passage Bio during the 4th quarter worth approximately $405,000. Finally, Renaissance Technologies LLC grew its holdings in Passage Bio by 8.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock worth $1,287,000 after acquiring an additional 8,300 shares during the last quarter. 53.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on PASG shares. Oppenheimer lowered their target price on Passage Bio from $30.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, April 21st. Chardan Capital set a $7.00 price target on shares of Passage Bio and gave the company a “neutral” rating in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Passage Bio from a “sell” rating to a “hold” rating in a report on Saturday. TD Cowen lowered shares of Passage Bio from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Finally, Guggenheim cut shares of Passage Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 10th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Passage Bio presently has a consensus rating of “Hold” and a consensus price target of $13.25.

Passage Bio Company Profile

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.